Ensysce Biosciences, Inc. Overview
Pro stress-test →Ensysce Biosciences is a clinical-stage pharmaceutical company focused on developing a new class of safer opioid medicines for severe pain, leveraging proprietary Trypsin-Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR) platforms to advance tamper-resistant therapeutic options designed to minimize the risk of opioid abuse and oral overdose while preserving strong analgesic efficacy. The company addresses a critical public health need by engineering prescription drugs with built-in abuse and overdose protection.
Strategic Profile
Pro stress-test →Ensysce announced on February 25, 2026 that its Board has launched a formal review of strategic alternatives to enhance shareholder value, which may include partnerships, licensing, capital formation, business combinations, asset sales, or other corporate transactions. Recent milestones include expansion of its opioid and ADHD patent portfolios, progress in the pivotal Phase 3 PF614-301 trial, and participation in several 2026 scientific and industry events.
Competitive Landscape
Pro stress-test →Ensysce competes in the safer opioid space against major pharmaceutical players developing abuse-deterrent formulations (e.g., Purdue Pharma, Collegium Pharmaceutical, Naurex). Ensysce's differentiation lies in its proprietary TAAP and MPAR platform technologies that provide tamper resistance and multi-pill abuse resistance. The company also competes for partnerships and capital with other clinical-stage biotech firms addressing opioid-related public health challenges.
Industry Context
Ensysce Biosciences, Inc. operates in Pharmaceutical - Clinical-Stage Biotech (Opioid Safety/Abuse Prevention).
Key facts
Founded: 2009 · Headquarters: La Jolla, California, United States · Employees: N/A · Revenue: N/A · Market cap: N/A